FDA firms up JAK inhibitor warnings after Xeljanz review
FDA holds back from action over Xeljanz safety study
Bad news for Pfizer as blockbuster Xeljanz flunks safety study
Pfizer’s janus kinase (JAK) inhibitor drug Xeljanz (tofacitinib) has received expanded approval from the FDA for adults with moderately-to-severely-active ulcerative colitis.
FDA approves oral treatment for ulcerative colitis